Atherosclerosis / Dyslipidaemia Flashcards

1
Q

Atherosclerosis Definition

A

Atherosclerosis is a lengthy progressive process characterised by the formation of local elevated lesions in the intima of large (aorta) and medium-sized vessels (coronary arteries) - termed atherosclerotic plaques

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Atherosclerosis Progression

A

The development of atherosclerotic plaques requires vessel damage and tissue response. Of note is that LDL migration to the intima is essential for this process.

  • Initial lesion
    • Histologically normal
    • Macrophage infiltrate
    • Isolated foam cells
  • Fatty streak
    • Intracellular lipid accumulation
  • Intermediate lesion
    • Addition of small extracellular lipid accumulation
  • Atheroma
    • Core of extracellular lipid
  • Fibroatheroma
    • Fibrotic/calcific changes
  • Complicated lesion
    • Surface defect
    • Haematoma/haemorrhage
    • Thrombosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Clinical Presentation of Atherosclerosis

A
  • Asymptomatic
    • Progressive lumen narrowing due to high grade plaque stenosis
    • Acute atherothrombic occlusion (ruptured plaque exposing collagen, lipid debris leading to coagulation)
    • Embolisation of distal arterial bed (detachment of small thrombus fragments)
    • Ruptured abdominal atherosclerotic aneurysm
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Examples of progressive lumen narrowing due to high grade plaque stenosis

A
  • Stable angina pectoris (stenosed coronary artery)
    • Intermittent claudication (iliac, femoral or popliteal stenosis)
    • Tissue ischaemia (renal atrophy)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Examples of acute atherothrombic occlusion

A
  • MI (coronary arteries)
    • Stroke (carotid arteries)
    • Lower limb gangrene (iliac, femoral or popliteal arteries)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Lipid Targets

A
CVD/CHD Prevention (Units in mmol/L)
LDL-C < 2.0 (stasis)
OR LDL-C < 1.8 (reduce deposits)
TC < 4.0
HDL-C > 1.0
TG < 2.0
Non-HDL-C < 2.5
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

High Risk Dyslipidaemia Populations

A
  • Symptomatic CHD, CVD or PVD
    • DM
    • Early family history of CHD
    • Familial hypercholesterolaemia
    • Aboriginal or Torres Straight Islanders
    • HTN
    • Males
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Dyslipidaemia Non-Pharmacological Management

A
  • Dietary modifications
    * Reduce fats
    * Saturated and trans
    * Mono- and polyunsaturated
    * Increase soluble fibre
    * Introduce plant sterol-enriched milk, margarine or cheese products
    * Most effective (approx LDL-C reduction of 10-15%)
    * Limit alcohol
    • Lose weight & increase physical activity
      • Most effective in increasing HDL-C
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Dyslipidaemia Pharmacological Management

A
  • Measure baseline CK and ALT prior to pharmacological management
    • Predominant Elevation of LDL-C
      • 1st line
        • Statin
      • 2nd line
        • Ezetimibe
        • Bile Acid Binding Resins
        • Nicotinic acids
        • Fibrates
    • Predominant Elevation of TG
      • Usually associated with low HDL-C
      • Increased risk of pancreatitis
      • 1st line
        • Fibrates and fish oil (omega 3)
      • 2nd line
        • Add Nicotinic acid
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q
Statin Overview
(incl generic name, mechanism and common side effects)
A

Generic Name

  • Atorvastatin
  • Rosuvastatin

Mechanism of Action
* Inhibit HMG CoA reductase

Side Effects
* Myopathy (raised CK)
(increased with nicotinic acid or vibrates)
* Raised ALT/AST

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q
Ezetimibe Overview
(incl mechanism and common side effects)
A

Mechanism of Action
* Inhibits cholesterol absorption

Side Effects

  • Myopathy
  • Raised ALT/AST
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Bile Acid Binding Resins Overview

incl generic name, mechanism and common side effects

A

Generic Name

  • Cholestyramine
  • Colestipol

Mechanism of Action

  • Increase excretion of bile acids
  • Causing more cholesterol to be converted to bile acids.

Side Effects

  • Gut related
    • Bloating
    • Abdominal discomfort
    • Diarrhoea
    • Constipation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Nicotinic Acids Overview

incl mechanism and common side effects

A

Mechanism of Action
* Reduce release of VLDL and thus lower TG

Side Effects

  • Prostaglandin mediated
    • Flushing
    • Dizziness
    • Palpitations
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q
Fibrates Overview
(incl generic name, mechanism and common side effects)
A

Generic Name
* Fenofibrate

Mechanism of Action

  • Promote lipoprotein lipase activity
  • Causing increased TG lipolysis

Side Effects
* Myositis-like syndrome
(increased with Statin)
* Gallstones - increased cholesterol in bile

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Atherosclerosis Procedural Management

A

Endarterectomy
- Technique where the atheromatous intima is cored out from the media

Percutaneous Angioplasty
- Balloon open the stenosed vessel and can have a stent placed for long term support

Surgical bypass
- Segments of the saphenous vein or radial artery are used to bypass affected areas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Lipid lowering medications and their impact on LDL, HDL & TG

A

LDL-C (decrease)

  • Statins - 18-55%
  • Fibrates - 5-20%
  • Nicotinic Acids - 5-25%
  • Bile Acid Binding Resins - 15-30%
  • Ezetimibe 18-20%

HDL-C (increase)

  • Statins - 5-15%
  • Fibrates - 10-20%
  • Nicotinic Acids - 15-35%
  • Bile Acid Binding Resins - 3-5%
  • Ezetimibe - 1-4%

TG (decrease)

  • Statins - 7-30%
  • Fibrates - 20-50%
  • Nicotinic Acids - 20-50%
  • Bile Acid Binding Resins - No change
  • Ezetimibe - 8%